DLBCL Subtype Response Patterns: Optimizing Treatment Selection
Experts discuss polatuzumab’s effectiveness across germinal center B-cell (GCB) and activated B-cell (ABC) diffuse large B-cell lymphoma (DLBCL) subgroups, including updates to published data. They also explore how different molecular classification methods compare in clinical practice to guide treatment selection, with insights on differential responses across specific molecular or clinical subgroups.
Video content above is prompted by the following:
Please discuss polatuzumab’s effectiveness across GCB and ABC DLBCL subgroups, including any updates to the published data.
• How do different molecular classification methods compare in clinical practice, and how does this information guide your treatment selection for your patients?
• Based on current evidence, which specific molecular or clinical subgroups show differential responses to various treatment approaches?
